MGL-3196
Phase 3Small molecule
Madrigal PharmaceuticalsMGL-3196 is one of 118 small molecule programs targeting Familial Hypercholesterolemia. It is currently in Phase 3.
3
Indications
10
Total Trials
1
Active Trials
117
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
113 competitors in Fibrosis
#DrugCompanyPhaseTrials
1Gleevec
NovartisPhase 3
PEG-Intron
Merck & Co.Phase 3
Atacand
AstraZenecaPhase 3
Esbriet
LLegacy Health System
Phase 3
Ofev
Boehringer IngelheimPhase 3
Ocaliva
IIntercept Pharmaceuticals
Phase 3
Myfortic
NovartisPhase 3
Ozempic
Novo NordiskPhase 2
Nolvadex
AstraZenecaPhase 2
Trental
VValidus Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Interaction3 trials
Non-Alcoholic Steatohepatitis1 trial
Hepatic Impairment1 trial
3 more indications
Familial Hypercholesterolemia1 trial
Fibrosis1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MGL-3196. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company